263 related articles for article (PubMed ID: 35139880)
41. A Simple Three-dimensional Hydrogel Platform Enables
Hribar KC; Wheeler CJ; Bazarov A; Varshneya K; Yamada R; Buckley P; Patil CG
Mol Cancer Ther; 2019 Mar; 18(3):718-725. PubMed ID: 30755456
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET.
Wu W; Bi C; Credille KM; Manro JR; Peek VL; Donoho GP; Yan L; Wijsman JA; Yan SB; Walgren RA
Clin Cancer Res; 2013 Oct; 19(20):5699-710. PubMed ID: 23989980
[TBL] [Abstract][Full Text] [Related]
43. [Establishment of Patient-Derived Xenograft (PDX) Zebrafish Model of Multiple Myeloma and Its Application in Drug Screening].
Yu Z; Li Y; Wang KF; Wang L; Hao M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1745-1749. PubMed ID: 38071055
[TBL] [Abstract][Full Text] [Related]
44. PDX models of human lung squamous cell carcinoma: consideration of factors in preclinical and co-clinical applications.
Jung HY; Kim TH; Lee JE; Kim HK; Cho JH; Choi YS; Shin S; Lee SH; Rhee H; Lee HK; Choi HJ; Jang HY; Lee S; Kang JH; Choi YA; Lee S; Lee J; Choi Y; Kim J
J Transl Med; 2020 Aug; 18(1):307. PubMed ID: 32762722
[TBL] [Abstract][Full Text] [Related]
45. Real-time evaluation of glioblastoma growth in patient-specific zebrafish xenografts.
Almstedt E; Rosén E; Gloger M; Stockgard R; Hekmati N; Koltowska K; Krona C; Nelander S
Neuro Oncol; 2022 May; 24(5):726-738. PubMed ID: 34919147
[TBL] [Abstract][Full Text] [Related]
46. Porous Paclitaxel Mesh Reduces Local Recurrence in Patient-Derived Xenograft Resection Model.
Tsai LL; Fitzgerald DM; Liu R; Korunes-Miller JT; Neal E; Hung YP; Bilton S; Hata A; Grinstaff MW; Colson YL
Ann Thorac Surg; 2023 Jul; 116(1):181-188. PubMed ID: 36376135
[TBL] [Abstract][Full Text] [Related]
47. Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies.
Eckhardt BL; Gagliardi M; Iles L; Evans K; Ivan C; Liu X; Liu CG; Souza G; Rao A; Meric-Bernstam F; Ueno NT; Bartholomeusz GA
PLoS One; 2018; 13(5):e0195932. PubMed ID: 29768500
[TBL] [Abstract][Full Text] [Related]
48. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.
Wang D; Pham NA; Tong J; Sakashita S; Allo G; Kim L; Yanagawa N; Raghavan V; Wei Y; To C; Trinh QM; Starmans MH; Chan-Seng-Yue MA; Chadwick D; Li L; Zhu CQ; Liu N; Li M; Lee S; Ignatchenko V; Strumpf D; Taylor P; Moghal N; Liu G; Boutros PC; Kislinger T; Pintilie M; Jurisica I; Shepherd FA; McPherson JD; Muthuswamy L; Moran MF; Tsao MS
Int J Cancer; 2017 Feb; 140(3):662-673. PubMed ID: 27750381
[TBL] [Abstract][Full Text] [Related]
49. PDXGEM: patient-derived tumor xenograft-based gene expression model for predicting clinical response to anticancer therapy in cancer patients.
Kim Y; Kim D; Cao B; Carvajal R; Kim M
BMC Bioinformatics; 2020 Jul; 21(1):288. PubMed ID: 32631229
[TBL] [Abstract][Full Text] [Related]
50. Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.
Yu J; Qin B; Moyer AM; Sinnwell JP; Thompson KJ; Copland JA; Marlow LA; Miller JL; Yin P; Gao B; Minter-Dykhouse K; Tang X; McLaughlin SA; Moreno-Aspitia A; Schweitzer A; Lu Y; Hubbard J; Northfelt DW; Gray RJ; Hunt K; Conners AL; Suman VJ; Kalari KR; Ingle JN; Lou Z; Visscher DW; Weinshilboum R; Boughey JC; Goetz MP; Wang L
Breast Cancer Res; 2017 Dec; 19(1):130. PubMed ID: 29212525
[TBL] [Abstract][Full Text] [Related]
51. The triptolide derivative MRx102 inhibits Wnt pathway activation and has potent anti-tumor effects in lung cancer.
Reno TA; Tong SW; Wu J; Fidler JM; Nelson R; Kim JY; Raz DJ
BMC Cancer; 2016 Jul; 16():439. PubMed ID: 27400883
[TBL] [Abstract][Full Text] [Related]
52. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
Dai B; Yan S; Lara-Guerra H; Kawashima H; Sakai R; Jayachandran G; Majidi M; Mehran R; Wang J; Bekele BN; Baladandayuthapani V; Yoo SY; Wang Y; Ying J; Meng F; Ji L; Roth JA
PLoS One; 2015; 10(6):e0123967. PubMed ID: 26053020
[TBL] [Abstract][Full Text] [Related]
53. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
54. Zebrafish xenograft model for studying mechanism and treatment of non-small cell lung cancer brain metastasis.
Fan RY; Wu JQ; Liu YY; Liu XY; Qian ST; Li CY; Wei P; Song Z; He MF
J Exp Clin Cancer Res; 2021 Nov; 40(1):371. PubMed ID: 34801071
[TBL] [Abstract][Full Text] [Related]
55. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival.
Pergolini I; Morales-Oyarvide V; Mino-Kenudson M; Honselmann KC; Rosenbaum MW; Nahar S; Kem M; Ferrone CR; Lillemoe KD; Bardeesy N; Ryan DP; Thayer SP; Warshaw AL; Fernández-Del Castillo C; Liss AS
PLoS One; 2017; 12(8):e0182855. PubMed ID: 28854237
[TBL] [Abstract][Full Text] [Related]
56. Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?
Merk J; Rolff J; Dorn C; Leschber G; Fichtner I
Eur J Cardiothorac Surg; 2011 Jul; 40(1):e29-33. PubMed ID: 21420313
[TBL] [Abstract][Full Text] [Related]
57. Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
Ono N; Yamazaki T; Tsukaguchi T; Fujii T; Sakata K; Suda A; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2013 Oct; 104(10):1346-52. PubMed ID: 23863134
[TBL] [Abstract][Full Text] [Related]
58. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
Lee HW; Lee JI; Lee SJ; Cho HJ; Song HJ; Jeong DE; Seo YJ; Shin S; Joung JG; Kwon YJ; Choi YL; Park WY; Lee HM; Seol HJ; Shim YM; Joo KM; Nam DH
Clin Cancer Res; 2015 Mar; 21(5):1172-82. PubMed ID: 25549722
[TBL] [Abstract][Full Text] [Related]
59. Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma.
Wu L; Allo G; John T; Li M; Tagawa T; Opitz I; Anraku M; Yun Z; Pintilie M; Pitcher B; Liu G; Feld R; Johnston MR; de Perrot M; Tsao MS
Clin Cancer Res; 2017 Feb; 23(4):1060-1067. PubMed ID: 27683181
[No Abstract] [Full Text] [Related]
60. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
Zhang L; Nomie K; Zhang H; Bell T; Pham L; Kadri S; Segal J; Li S; Zhou S; Santos D; Richard S; Sharma S; Chen W; Oriabure O; Liu Y; Huang S; Guo H; Chen Z; Tao W; Li C; Wang J; Fang B; Wang J; Li L; Badillo M; Ahmed M; Thirumurthi S; Huang SY; Shao Y; Lam L; Yi Q; Wang YL; Wang M
Clin Cancer Res; 2017 Aug; 23(15):4212-4223. PubMed ID: 28348046
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
